THC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Buy now for a near-term rebound setup. THC is trading near support (S1 ~186) at 189.28 with an oversold-leaning RSI and a MACD that is still negative but improving (bearish momentum fading). Options positioning is notably bullish (low put/call), and Wall Street targets remain far above the current price despite a couple of recent trims. The main offsets are heavy insider selling and Q3 profit/EPS contraction, but for an impatient buyer looking for an entry without waiting, the current location near support offers a favorable risk/reward for a bounce toward ~192–199 first, then ~202 if momentum follows through.
Price/levels: Post-market 189.28 is below the pivot (192.31), sitting closer to support S1 (186.09) than resistance R1 (198.53). This is a tactically favorable zone for a rebound attempt. Momentum: MACD histogram at -0.652 is below zero (trend still bearish), but it is negatively contracting, signaling downside momentum is weakening. RSI: RSI(6) = 31.54 (near-oversold territory). This often aligns with short-term mean reversion bounces, especially when price is near support. Moving averages: Converging MAs indicate consolidation after a move—often a prelude to a directional break; with RSI depressed near support, the higher-probability immediate move is a bounce rather than a fresh breakdown. Key roadmap: Support 186.09 then 182.25. Upside checkpoints 192.31 (pivot), 198.53 (R1), 202.37 (R2). Pattern-based odds: Similar pattern clustering suggests positive skew over 1 week to 1 month (provided stats indicate a strong 1-week/1-month upside bias).
Intellectia Proprietary Trading Signals
Options sentiment is bullish (call-heavy, very low put/call on volume).
Hedge funds are aggressively buying (reported +337.36% QoQ buying amount).
Analyst community remains broadly positive (Buy/Overweight/Outperform) with price targets far above spot.
Technical setup favors mean reversion: price near support with RSI near oversold and MACD downside momentum fading.
Next earnings catalyst: QDEC 2025 earnings on 2026-02-11 (pre-market) can re-rate the stock if results/guide are strong.
Insiders are selling aggressively (reported selling amount +1492.05% last month), which can cap upside near-term.
Recent analyst target trims cite policy/payor-mix headwinds (ACA subsidy extension odds and 2026 hospital backdrop).
Profitability is trending down YoY (Q3 net income/EPS declines), which can pressure multiples if it persists.
Technical trend is not fully repaired: MACD is still below zero and price is below the pivot (192.31).
Latest quarter: 2025/Q3. Growth: Revenue 5.289B, up +3.26% YoY (top-line growth remains positive). Profitability: Net income 342M, down -27.54% YoY; EPS 3.86, down -21.06% YoY. Margins: Gross margin 78.28%, down -0.56% YoY. Read-through: The business is growing revenues, but earnings and margins compressed meaningfully YoY—fundamentals are not the driver of the current bullish setup; the buy case is more positioning/technical/expectations-driven into the next catalyst window.
Recent trend: Predominantly bullish ratings maintained (Buy/Overweight/Outperform), with price targets mostly raised through Nov–Dec after strong Q3, then modestly trimmed in early Jan on policy/payor-mix concerns. Notable changes:
